On Tuesday, Lyra Therapeutics Inc (NASDAQ: LYRA) was -2.97% drop from the session before settling in for the closing price of $0.19. A 52-week range for LYRA has been $0.16 – $6.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 98.14%. When this article was written, the company’s average yearly earnings per share was at -5.36%. With a float of $54.79 million, this company’s outstanding shares have now reached $65.46 million.
The extent of productivity of a business whose workforce counts for 88 workers is very important to gauge. In terms of profitability, gross margin is -816.72%, operating margin of -6894.43%, and the pretax margin is -6632.36%.
Lyra Therapeutics Inc (LYRA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lyra Therapeutics Inc stocks. The insider ownership of Lyra Therapeutics Inc is 16.29%, while institutional ownership is 46.47%.
Lyra Therapeutics Inc (LYRA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.36% per share during the next fiscal year.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
You can see what Lyra Therapeutics Inc (LYRA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
The latest stats from [Lyra Therapeutics Inc, LYRA] show that its last 5-days average volume of 1.36 million was inferior to 1.82 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 21.02%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 14.83%, which indicates a significant decrease from 31.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.00% in the past 14 days, which was lower than the 94.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2079, while its 200-day Moving Average is $0.9159. Now, the first resistance to watch is $0.1962. This is followed by the second major resistance level at $0.2033. The third major resistance level sits at $0.2078. If the price goes on to break the first support level at $0.1846, it is likely to go to the next support level at $0.1801. The third support level lies at $0.1730 if the price breaches the second support level.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
There are 65,458K outstanding shares of the company, which has a market capitalization of 12.38 million. As of now, sales total 1,560 K while income totals -62,680 K. Its latest quarter income was 200 K while its last quarter net income were -11,870 K.
